In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108134
Title:
In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.
Authors:
Bronchud, M H; Potter, M R; Morgenstern, Godfrey R; Blasco, M J; Scarffe, J Howard; Thatcher, Nick; Crowther, Derek; Souza, L M; Alton, N K; Testa, Nydia G; Dexter, T Michael
Abstract:
Twelve patients with small cell lung cancer were treated with recombinant human granulocyte colony-stimulating factor, rhG-CSF, given by continuous infusion at doses ranging from 1 to 40 micrograms kg-1 day-1. Patients received the rhG-CSF before the start of intensive chemotherapy and after alternate cycles of chemotherapy. Several in vitro assays were performed using peripheral blood neutrophils and marrow progenitor cells collected from patients prior to and after infusion of the growth factor. Peripheral blood neutrophils were tested for mobility and phagocytic activity. In addition, in vitro clonogenic assays of marrow haemopoietic progenitor cells and analysis of bone marrow trephines and aspirates were carried out. We found that rhG-CSF in vivo has at least two main effects: (a) an early fall in peripheral neutrophils, within the first hour, followed by a rapid influx of mature neutrophils into the circulatory pool; (b) stimulation of proliferation and differentiation of neutrophil precursors in the bone marrow. Neutrophils released into the circulation were normal in tests of their mobility and phagocytic activity.
Affiliation:
Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.
Citation:
In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. 1988, 58 (1):64-9 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Jul-1988
URI:
http://hdl.handle.net/10541/108134
PubMed ID:
2458748
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorBronchud, M Hen
dc.contributor.authorPotter, M Ren
dc.contributor.authorMorgenstern, Godfrey Ren
dc.contributor.authorBlasco, M Jen
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorThatcher, Nicken
dc.contributor.authorCrowther, Dereken
dc.contributor.authorSouza, L Men
dc.contributor.authorAlton, N Ken
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorDexter, T Michaelen
dc.date.accessioned2010-07-22T08:27:19Z-
dc.date.available2010-07-22T08:27:19Z-
dc.date.issued1988-07-
dc.identifier.citationIn vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. 1988, 58 (1):64-9 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid2458748-
dc.identifier.urihttp://hdl.handle.net/10541/108134-
dc.description.abstractTwelve patients with small cell lung cancer were treated with recombinant human granulocyte colony-stimulating factor, rhG-CSF, given by continuous infusion at doses ranging from 1 to 40 micrograms kg-1 day-1. Patients received the rhG-CSF before the start of intensive chemotherapy and after alternate cycles of chemotherapy. Several in vitro assays were performed using peripheral blood neutrophils and marrow progenitor cells collected from patients prior to and after infusion of the growth factor. Peripheral blood neutrophils were tested for mobility and phagocytic activity. In addition, in vitro clonogenic assays of marrow haemopoietic progenitor cells and analysis of bone marrow trephines and aspirates were carried out. We found that rhG-CSF in vivo has at least two main effects: (a) an early fall in peripheral neutrophils, within the first hour, followed by a rapid influx of mature neutrophils into the circulatory pool; (b) stimulation of proliferation and differentiation of neutrophil precursors in the bone marrow. Neutrophils released into the circulation were normal in tests of their mobility and phagocytic activity.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBone Marrow-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshChemotaxis, Leukocyte-
dc.subject.meshColony-Forming Units Assay-
dc.subject.meshColony-Stimulating Factors-
dc.subject.meshDrug Evaluation-
dc.subject.meshGranulocyte Colony-Stimulating Factor-
dc.subject.meshGranulocytes-
dc.subject.meshHumans-
dc.subject.meshLeukocyte Count-
dc.subject.meshLung Neoplasms-
dc.subject.meshNeutropenia-
dc.subject.meshNeutrophils-
dc.subject.meshPhagocytosis-
dc.subject.meshRecombinant Proteins-
dc.titleIn vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.